Start a ProjectMICRONEEDLE APPLICATION
Initial inputs include payload properties, total dose, target duration, acceptable burst and residual release, stability data, administration concept and intended product pathway. Practical patch area and loading capacity constrain route selection.
Development can assess structure and payload distribution, insertion, tip separation or integrity, in-vitro release, formulation stability and batch consistency. In-vivo duration and safety require a justified study design and are not inferred from in-vitro data alone.
Layered dissolving structures, PLGA microparticle systems, microcrystal approaches and swelling or implantable concepts create different release and removal considerations. Selection is driven by payload, dose, duration, material compatibility and process feasibility.
Stage outputs can include a release-target assessment, candidate architecture, prototype and analytical data, identified scale-up risks and a recommendation for formulation, process or preclinical work. No fixed duration is promised before data are available.
CASMN team publications describe layered and PLGA-microparticle microneedle research for sustained delivery. These studies are model-specific evidence, not proof of an approved long-acting platform for every payload.
Feasibility and performance are project-specific and depend on payload properties, target dose, product design, analytical strategy and intended use. Technical Review — Reviewed by: CASMN R&D Team · Last reviewed: August 2026.
The team reviews payload properties, target dose, stability, intended use, delivery requirements and manufacturing constraints.
Technology selection is made project by project after reviewing dose, release profile, product use and process requirements.
No. Publications provide scientific context and do not establish regulatory approval, clinical performance or commercial availability.
Send your target product, payload, development stage and cooperation scope to our business development team.
Start a Project